SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate a major catalyst from the final survival event in the Phase 3 REGAL trial, with the stock seeing intense volatility driven by a massive short squeeze. Community members are actively debating the timing of a potential buyout and the drug's long-term curative potential, while the tightening liquidity and extreme borrow costs continue to trap short sellers in a high-pressure environment.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is experiencing a significant defensive rotation as market capital pivots from high-beta technology and AI toward established healthcare stalwarts with visible cash flows. The stock's positive performance is further bolstered by institutional confidence in its oncology pipeline, a fresh dividend hike, and active speculation regarding the potential sale of its multi-billion dollar orthopedics division.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant attention from the investment community due to its strategic positioning in ruggedized edge computing, which is essential for the expanding physical AI, robotics, and defense infrastructure sectors. Discussions are heavily focused on the company's strong contract pipeline, recent earnings performance, and positive momentum from upcoming index inclusion, with many participants viewing it as an under-the-radar player poised to capitalize on the shift of AI workloads beyond traditional data centers.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors debate whether the recent volatility represents a healthy consolidation phase or a deeper structural correction within the AI hardware supply chain. The community is focused on the critical role of Indium Phosphide (InP) substrates as a production bottleneck for high-speed AI optical networking, with ongoing discussions centered on whether recent price fluctuations offer an accumulation window or signal potential downside risks.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella is seeing significant investor attention following reports that the company is working with bankers to explore strategic options, including a potential sale. The community is actively discussing the implications of this M&A speculation, with many highlighting its long-term potential as a key enabler in the edge AI and robotics hardware supply chain.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

The community is actively discussing the potential acquisition of Churchill Capital Corp XI following the merger announcement with Agility Robotics, with many investors debating the long-term viability of the robotics sector and comparing the situation to previous SPAC experiences. Bullish sentiment is driven by the company's backing from major tech players, while others remain skeptical, warning of potential volatility and cautioning against post-merger price fluctuations.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF is currently navigating institutional volatility and defensive hedging, with the community actively debating whether it serves as a reliable anchor during rotation into tech-heavy sectors or if the broader market is flashing signs of an over-extended bubble. Investors are primarily focused on the ETF's utility as a long-term 'set it and forget it' compounding tool while weighing the impact of elevated CapEx and macroeconomic uncertainty on future growth.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as a top healthcare leader due to groundbreaking Phase 3 clinical data for its obesity and diabetes pipeline, which has ignited investor excitement regarding its long-term growth prospects. The community is actively discussing this news, alongside broader market rotation into defensive, high-quality pharmaceutical names as participants look to balance their portfolios.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is currently trending due to a sharp sell-off following an earnings report where revenue growth impressed, but rising logistics and fintech investments raised investor concerns over near-term margin pressure. The community remains deeply divided between those viewing the pullback as a historic buying opportunity for a Latin American e-commerce powerhouse and skeptics concerned about valuation multiples and the sustainability of aggressive reinvestment strategies.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending due to significant sector rotation as investors shift capital from overextended large-cap tech into the biotech space. The community is actively discussing bullish price structures, potential M&A activity, and biotech's role as a defensive rotation as broad markets search for direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.

International Regulatory Momentum Becoming Key Modern Drug Development Driver

NeOnc Technologies Holdings (NASDAQ:NTHI) remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.

NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:15 a.m. ET. Investors and the general public are invited to listen...

Bristol Myers Squibb (BMY) Stock Moves -1.14%: What You Should Know

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.28, representing a -1.14% change from its previous close.

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on August 3, 2026, to stockholders of record at the close of business on...

Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.

Is it a Good Idea to Invest in Immunocore Stock Right Now?

IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor

Equity

Bullish Sentiment

Track BMY stock price, charts, news and real-time market activity on Stocktwits. Join the BMY message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Bristol-Myers Squibb Co stock.

BMY Stock Price Today - Bristol Myers Squibb News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$57.52
Prev Close	$55.39
Open	$55.40
Dividend Yield	4.62%
50-Day Moving Average	$57.09
Beta	0.31
Avg. Volume	10.72M
PE Ratio	15.55

52-Week High	$62.89
52-Week Low	$42.52
Market Capitalization	$117.46B
EPS (Annual)	$3.46
Price to Book	5.64
Revenue Per Employee	$1.48M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMYBristol-Myers Squibb Co.

Latest BMY News